Before revision:   These results support studying \alpha_1-AR antagonists for preventing ARDS and reducing mortality in pneumonia and acute respiratory distress, as well as highlight the need for prospective trials of \alpha_1-AR antagonists to assess their efficacy in preventing cytokine storm syndrome and death in COVID-19.
After revision:  These results support studying \alpha_1-AR antagonists for preventing ARDS and reducing mortality in pneumonia and acute respiratory distress, as well as highlight the need for prospective trials testing whether prophylactic \alpha-blockers improve outcomes in diseases with a prominent hyperinflammatory component such as COVID-19.